GB201802339D0 - Immunogenic composition - Google Patents

Immunogenic composition

Info

Publication number
GB201802339D0
GB201802339D0 GBGB1802339.0A GB201802339A GB201802339D0 GB 201802339 D0 GB201802339 D0 GB 201802339D0 GB 201802339 A GB201802339 A GB 201802339A GB 201802339 D0 GB201802339 D0 GB 201802339D0
Authority
GB
United Kingdom
Prior art keywords
immunogenic composition
immunogenic
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1802339.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to GBGB1802339.0A priority Critical patent/GB201802339D0/en
Publication of GB201802339D0 publication Critical patent/GB201802339D0/en
Priority to KR1020207025858A priority patent/KR20200121825A/ko
Priority to IL276661A priority patent/IL276661B2/en
Priority to SG11202007676RA priority patent/SG11202007676RA/en
Priority to CN201980025676.7A priority patent/CN112153980A/zh
Priority to EA202091690A priority patent/EA202091690A1/ru
Priority to ARP190100345A priority patent/AR114627A1/es
Priority to EP19706423.1A priority patent/EP3752183A1/en
Priority to BR112020016373-2A priority patent/BR112020016373A2/pt
Priority to MX2020008454A priority patent/MX2020008454A/es
Priority to PCT/EP2019/053463 priority patent/WO2019158537A1/en
Priority to JP2020565545A priority patent/JP2021514387A/ja
Priority to US16/968,895 priority patent/US11426455B2/en
Priority to AU2019221496A priority patent/AU2019221496B2/en
Priority to CA3090609A priority patent/CA3090609A1/en
Priority to US17/869,055 priority patent/US20230052495A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
GBGB1802339.0A 2018-02-13 2018-02-13 Immunogenic composition Ceased GB201802339D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB1802339.0A GB201802339D0 (en) 2018-02-13 2018-02-13 Immunogenic composition
CA3090609A CA3090609A1 (en) 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens
ARP190100345A AR114627A1 (es) 2018-02-13 2019-02-12 Composición inmunogénica
BR112020016373-2A BR112020016373A2 (pt) 2018-02-13 2019-02-12 Composição imunogênica compreendendo antígenos de estafilococos
SG11202007676RA SG11202007676RA (en) 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens
CN201980025676.7A CN112153980A (zh) 2018-02-13 2019-02-12 包含葡萄球菌抗原的免疫原性组合物
EA202091690A EA202091690A1 (ru) 2018-02-13 2019-02-12 Иммуногенная композиция, содержащая стафилококковые антигены
KR1020207025858A KR20200121825A (ko) 2018-02-13 2019-02-12 포도상구균 항원을 포함하는 면역원성 조성물
EP19706423.1A EP3752183A1 (en) 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens
IL276661A IL276661B2 (en) 2018-02-13 2019-02-12 Immunogenic preparation containing staphylococcal antigens
MX2020008454A MX2020008454A (es) 2018-02-13 2019-02-12 Composicion inmunogenica que comprende antigenos estafilococicos.
PCT/EP2019/053463 WO2019158537A1 (en) 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens
JP2020565545A JP2021514387A (ja) 2018-02-13 2019-02-12 ブドウ球菌抗原を含む免疫原性組成物
US16/968,895 US11426455B2 (en) 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens
AU2019221496A AU2019221496B2 (en) 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens
US17/869,055 US20230052495A1 (en) 2018-02-13 2022-07-20 Immunogenic composition comprising staphylococcal antigens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1802339.0A GB201802339D0 (en) 2018-02-13 2018-02-13 Immunogenic composition

Publications (1)

Publication Number Publication Date
GB201802339D0 true GB201802339D0 (en) 2018-03-28

Family

ID=61731342

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1802339.0A Ceased GB201802339D0 (en) 2018-02-13 2018-02-13 Immunogenic composition

Country Status (15)

Country Link
US (2) US11426455B2 (cg-RX-API-DMAC7.html)
EP (1) EP3752183A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021514387A (cg-RX-API-DMAC7.html)
KR (1) KR20200121825A (cg-RX-API-DMAC7.html)
CN (1) CN112153980A (cg-RX-API-DMAC7.html)
AR (1) AR114627A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019221496B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016373A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090609A1 (cg-RX-API-DMAC7.html)
EA (1) EA202091690A1 (cg-RX-API-DMAC7.html)
GB (1) GB201802339D0 (cg-RX-API-DMAC7.html)
IL (1) IL276661B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020008454A (cg-RX-API-DMAC7.html)
SG (1) SG11202007676RA (cg-RX-API-DMAC7.html)
WO (1) WO2019158537A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110511950A (zh) * 2019-07-29 2019-11-29 因之彩生物科技(武汉)有限公司 Pab蛋白在构建具有类伴侣样蛋白作用的融合蛋白表达载体中的应用
US12673102B2 (en) 2020-05-01 2026-07-07 Sinocelltech Ltd. Method for improving immunogenicity of protein/peptide antigen

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US20230045642A1 (en) 2019-12-19 2023-02-09 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
KR20220039610A (ko) 2020-09-21 2022-03-29 주식회사 엘지에너지솔루션 리튬 이차전지 활성화 방법 및 리튬 이차전지
CN121081612A (zh) * 2024-05-30 2025-12-09 江苏坤力生物制药有限责任公司 一种金黄色葡萄球菌纳米化抗原、含其的疫苗及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2730275T3 (es) * 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
CA2713241C (en) * 2008-01-31 2022-10-04 Timothy Foster Treatment of microbial infections
AU2015202532A1 (en) 2009-04-14 2015-06-04 Novartis Ag Compositions for immunising against Staphylococcus aureus
AU2010264538B2 (en) * 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
US20140037650A1 (en) 2009-07-24 2014-02-06 University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
WO2011138361A1 (en) * 2010-05-06 2011-11-10 Glycovaxyn Capsular gram-positive bacteria bioconjugate vaccines
AU2011274367B2 (en) * 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 感染防御ブドウ球菌抗原が関与する方法および組成物
HUE033072T2 (hu) 2010-12-22 2017-11-28 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
US9556281B2 (en) * 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
EP2890387A1 (en) * 2012-08-31 2015-07-08 Novartis AG Stabilised proteins for immunising against staphylococcus aureus
CN106163550A (zh) 2013-12-04 2016-11-23 格林考瓦因有限公司 通过大肠杆菌中合成的糖蛋白疫苗预防金黄色葡萄球菌感染
MX377794B (es) * 2014-03-26 2025-03-10 Glaxosmithkline Biologicals Sa Antigenos estafilococicos mutantes.
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110511950A (zh) * 2019-07-29 2019-11-29 因之彩生物科技(武汉)有限公司 Pab蛋白在构建具有类伴侣样蛋白作用的融合蛋白表达载体中的应用
CN110511950B (zh) * 2019-07-29 2022-03-08 因之彩生物科技(武汉)有限公司 Pab蛋白在构建具有类伴侣样蛋白作用的融合蛋白表达载体中的应用
US12673102B2 (en) 2020-05-01 2026-07-07 Sinocelltech Ltd. Method for improving immunogenicity of protein/peptide antigen

Also Published As

Publication number Publication date
SG11202007676RA (en) 2020-09-29
KR20200121825A (ko) 2020-10-26
EA202091690A1 (ru) 2020-11-27
BR112020016373A2 (pt) 2020-12-15
JP2021514387A (ja) 2021-06-10
CA3090609A1 (en) 2019-08-22
IL276661B2 (en) 2023-08-01
IL276661A (en) 2020-09-30
IL276661B1 (en) 2023-04-01
AR114627A1 (es) 2020-09-30
EP3752183A1 (en) 2020-12-23
US20230052495A1 (en) 2023-02-16
US20210023192A1 (en) 2021-01-28
AU2019221496A1 (en) 2020-08-27
AU2019221496B2 (en) 2022-12-08
US11426455B2 (en) 2022-08-30
MX2020008454A (es) 2021-03-25
CN112153980A (zh) 2020-12-29
WO2019158537A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
SG11202010821TA (en) Vaccine composition
GB201711635D0 (en) Immunogenic composition
IL271603A (en) Immunogenic preparations
GB201610599D0 (en) Immunogenic Composition
GB201811100D0 (en) Composition
GB201810492D0 (en) Composition
HUE068216T2 (hu) Aeroszolizálható készítmény
GB201804434D0 (en) Composition
SG11202009147UA (en) Vaccine compositions
IL291559A (en) Immunogenic preparations
EP3397277C0 (en) IMMUNOGENIC COMPOSITION
GB201820878D0 (en) Composition
GB201812145D0 (en) Composition
SG11202103389WA (en) Immunogenic compositions
GB201711637D0 (en) Immunogenic composition
GB201818827D0 (en) Composition
GB201801596D0 (en) Composition
GB201614485D0 (en) Immunogenic composition
EP3741388A4 (en) IMMUNOGENIC COMPOSITION
GB201901161D0 (en) Composition
GB201810024D0 (en) Composition
GB201703529D0 (en) Vaccine composition
GB201803692D0 (en) Immunogenic composition
GB201819861D0 (en) Composition
GB201818567D0 (en) Composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)